The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.
 
David Michael Jackman
No Relationships to Disclose
 
Opeyemi Jegede
No Relationships to Disclose
 
Marjorie Glass Zauderer
Honoraria - Medical Learning Institute
Consulting or Advisory Role - Aldeyra Therapeutics; Atara Biotherapeutics; GlaxoSmithKline; Novocure; Takeda
Research Funding - Atara Biotherapeutics (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Polaris (Inst); Sellas Life Sciences (Inst)
(OPTIONAL) Uncompensated Relationships - Mesothelioma Applied Research Foundation
 
Edith P. Mitchell
Leadership - Corvus Pharmaceuticals
Honoraria - Sanofi
Consulting or Advisory Role - Bristol Myers Squib; Genentech; Merck; Novartis
Speakers' Bureau - Ipsen
Research Funding - Genentech (Inst); sanofi (Inst)
 
James Zwiebel
No Relationships to Disclose
 
Robert James Gray
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda
 
Shuli Li
No Relationships to Disclose
 
Lisa McShane
No Relationships to Disclose
 
Lawrence Rubinstein
No Relationships to Disclose
 
David R Patton
No Relationships to Disclose
 
Paul M. Williams
Research Funding - Illumina (Inst)
Patents, Royalties, Other Intellectual Property - I was a co-inventor of the DLBCL cell of origin patent recently filed by the NIH
 
Stanley R. Hamilton
Stock and Other Ownership Interests - Johns Hopkins University School of Medicine
Consulting or Advisory Role - Bristol-Myers Squibb; Cell Medica/Kuur Therapeutics; Guardant Health; HalioDx; Loxo; Merck; Thermo Fisher Scientific
 
Barbara A. Conley
No Relationships to Disclose
 
Carlos L. Arteaga
Leadership - American Association for Cancer Research
Stock and Other Ownership Interests - Provista Diagnostics; Y-Trap Inc.
Consulting or Advisory Role - Athenex; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; H3 Biomedicine; Immunomedics; Lilly; Merck; Novartis; Origimed; Petra Pharma; Puma Biotechnology; Radius Health; Sanofi; Symphogen; Taiho Pharmaceutical; Third Rock Ventures
Research Funding - Bayer; Lilly; Pfizer; Puma Biotechnology; Radius Health; Takeda
Other Relationship - Susan G. Komen for the Cure
 
Lyndsay Harris
Patents, Royalties, Other Intellectual Property - Philips Healthcare
 
Peter J. O'Dwyer
Consulting or Advisory Role - Array BioPharma; Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Lilly
 
Alice P. Chen
No Relationships to Disclose
 
Keith Flaherty
Stock and Other Ownership Interests - Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Fount Therapeutics; Kinnate Biopharma; Loxo; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Array BioPharma; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Cell Medica; Debiopharm Group; FOGPharma; Genentech; Incyte; Lilly; Loxo; Merck; Neon Therapeutics; Novartis; Oncoceutics; Pierre Fabre; Roche; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - Debiopharm Group; Pierre Fabre